Insmed
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- -
- Employees
- 912
- Market Cap
- $13.2B
- Introduction
Insmed, Inc. is a global biopharmaceutical company, which engages in the development and commercialization of therapies for patients with rare diseases. Its focuses on Brensocatib, and Treprostinil Palmitil Inhalation Powder (TPIP) pipeline. The company was founded in 1988 and is headquartered in Bridgewater, NJ.
A Post Trial Access Study to Assess Treprostinil Palmitil Inhalation Powder (TPIP) for Participants With Pulmonary Arterial Hypertension (PAH)
- Conditions
- Pulmonary Arterial Hypertension
- First Posted Date
- 2025-04-23
- Last Posted Date
- 2025-04-23
- Lead Sponsor
- Insmed Incorporated
- Registration Number
- NCT06939647
A Study of the Efficacy and Safety of Brensocatib in Adults With Moderate to Severe Hidradenitis Suppurativa (HS)
- First Posted Date
- 2024-11-13
- Last Posted Date
- 2025-05-18
- Lead Sponsor
- Insmed Incorporated
- Target Recruit Count
- 204
- Registration Number
- NCT06685835
- Locations
- 🇺🇸
USA007, Sacramento, California, United States
🇺🇸USA026, Coral Gables, Florida, United States
🇺🇸USA021, Margate, Florida, United States
A Study to Assess the Relative Bioavailability of Brensocatib Pediatric Oral Solution to Oral Tablets in Healthy Participants
Phase 1
Completed
- Conditions
- Healthy Participants
- Interventions
- First Posted Date
- 2024-04-03
- Last Posted Date
- 2024-06-13
- Lead Sponsor
- Insmed Incorporated
- Target Recruit Count
- 24
- Registration Number
- NCT06344728
- Locations
- 🇺🇸
USA001, Dallas, Texas, United States
Single Dose Escalation Study of TR02 (Sustained Lipid Inhalation Technology [SLITâ„¢] Amikacin) in Participants With Cystic Fibrosis (CF) Having Chronic Infections of Pseudomonas Aeruginosa
- First Posted Date
- 2024-02-02
- Last Posted Date
- 2024-02-02
- Lead Sponsor
- Insmed Incorporated
- Target Recruit Count
- 18
- Registration Number
- NCT06238856
A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of C16TR for Inhalation With Tyvaso® Cohort in Healthy Participants
- First Posted Date
- 2024-01-05
- Last Posted Date
- 2024-01-05
- Lead Sponsor
- Insmed Incorporated
- Target Recruit Count
- 24
- Registration Number
- NCT06193031
- Locations
- 🇺🇸
USA001, Los Angeles, California, United States
A Study of the Palatability and Acceptability of Different Brensocatib Oral Liquid Formulations in Healthy Participants
- First Posted Date
- 2023-12-21
- Last Posted Date
- 2024-01-22
- Lead Sponsor
- Insmed Incorporated
- Target Recruit Count
- 20
- Registration Number
- NCT06178783
- Locations
- 🇺🇸
USA001, Dallas, Texas, United States
A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Treprostinil Palmitil Inhalation Powder (TPIP) in Healthy Participants
Phase 1
Completed
- Conditions
- Healthy Volunteers
- Interventions
- Drug: Placebo
- First Posted Date
- 2023-10-19
- Last Posted Date
- 2023-10-19
- Lead Sponsor
- Insmed Incorporated
- Target Recruit Count
- 42
- Registration Number
- NCT06091579
- Locations
- 🇺🇸
USA001, Austin, Texas, United States
A Study of the Efficacy and Safety of Brensocatib in Participants With Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP)
Phase 2
Active, not recruiting
- Conditions
- Chronic Rhinosinusitis Without Nasal Polyps
- Interventions
- First Posted Date
- 2023-08-28
- Last Posted Date
- 2025-05-11
- Lead Sponsor
- Insmed Incorporated
- Target Recruit Count
- 288
- Registration Number
- NCT06013241
- Locations
- 🇺🇸
USA004, Tulsa, Oklahoma, United States
🇦🇷ARG004, Rosario, Santa Fe, Argentina
🇦🇷ARG014, Mendoza, Argentina
A Study to Investigate Lung Deposition of Inhaled Amikacin-loaded Liposomes in Healthy Male Participants
Phase 1
Completed
- Conditions
- Healthy Volunteers
- Interventions
- Drug: Liposomal Amikacin for Inhalation
- First Posted Date
- 2023-08-21
- Last Posted Date
- 2023-08-21
- Lead Sponsor
- Insmed Incorporated
- Target Recruit Count
- 6
- Registration Number
- NCT05999942
A Study to Investigate Effect of Clarithromycin, a Strong CYP3A4 Inhibitor, on Brensocatib Pharmacokinetics in Healthy Participants
- First Posted Date
- 2023-07-28
- Last Posted Date
- 2023-12-11
- Lead Sponsor
- Insmed Incorporated
- Target Recruit Count
- 22
- Registration Number
- NCT05965570
- Locations
- 🇺🇸
USA001, Dallas, Texas, United States
© Copyright 2025. All Rights Reserved by MedPath